Clinical Trials Logo

Filter by:
NCT ID: NCT04549415 Completed - Clinical trials for Coronary Artery Disease

The Influence of Metformin on Chronic Heart Failure Clinical Course in Patients With Prediabetes

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

It is well known fact, that prediabetes is a predictor of high cardiovascular mortality, increasing the risk of developing such adverse cardiovascular events as myocardial infarction, stroke and sudden cardiac death. The key pathogenetic link in development of carbohydrates metabolism disorders (CMD) is insulin resistance (IR), which is one of the crucial mechanisms for the development and progression of chronic heart failure (CHF). IR disrupts the functioning of the myocardium due to endothelial dysfunction, inflammation, oxidative stress, remodeling and impaired myocardial metabolism. In condition of a combination of CMD and CHF the reverse development of hyperglycemia is also difficult due to hyperactivation of neurohormonal systems - renin-angiotensin-aldosterone system, in particular. So, drug therapy should neutralize the undesirable metabolic effects of hyperglycemia on the course of CHF, as well as prevent the development of micro- and macrovascular complications. The study will investigate the ability of metformin to impact on clinical and laboratory (neurohormonal, lipid profiles, renal function) parameters of ischemic etiology heart failure patients with prediabetes, as well as their quality of life and prognosis (incidence of adverse cardiovascular events). These tests will be assessed at the beginning and repeated after one year. At the end of the study we will investigate the difference between lifestyle modification effect and metformin treatment. The study is funded by Ministry of Education and Science of Kyrgyz Republic.

NCT ID: NCT03957759 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Early Signs of Altitude Illness in Patients With COPD

Start date: May 20, 2019
Phase:
Study type: Observational

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel.

NCT ID: NCT03955770 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.

Start date: May 20, 2019
Phase: Phase 4
Study type: Interventional

This will be a randomized, cross-over trial evaluating the efficacy of nasal high-flow oxygen therapy (HFOT) vs. low-flow oxygen therapy (LFOT) on cycling endurance in patients with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT03561675 Completed - Clinical trials for Acute Mountain Sickness

Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide in preventing acute mountain sickness in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03540914 Active, not recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function at rest in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03540901 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

Start date: May 22, 2018
Phase: Phase 4
Study type: Interventional

This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT03539367 Active, not recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03537924 Active, not recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function during exercise in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536520 Completed - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on visuo-motor learning performance in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536507 Completed - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on sleep disordered breathing in lowlanders older than 40 years travelling from 760 m to 3'100 m.